8-K: Tvardi Reports Q4/FY25 Results, TTI-101 HCC Data Delayed

Tvardi Therapeutics announced its fourth quarter and full-year 2025 financial results, showing reduced net losses, but also a delay in topline data for its TTI-101 hepatocellular carcinoma trial to the second half of 2026.

Summary

• Reported financial and operating results for the fourth quarter and full-year ended December 31, 2025.
• Topline data from the Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) is now anticipated in the second half of 2026, a delay to allow for data maturation, longitudinal and translational assessments, characterization of durability, and dose optimization.
• Results from the healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, remain on track for the second quarter of 2026.
• Additional analysis from the REVERT IPF Phase 2 trial demonstrated that TTI-101 was associated with a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo, and a 4.5-fold greater decline in IL-6.
• The cash runway is expected to be sufficient to fund operations into the fourth quarter of 2026 after clinical readouts.
• Net loss for the fourth quarter of 2025 was $7.3 million, an improvement from $12.7 million for the comparable period in 2024.
• Full-year 2025 net loss was $18.2 million, an improvement from $29.4 million for the full year 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While financial performance showed significant improvement with reduced net losses, the delay in key TTI-101 HCC data introduces uncertainty, partially offset by positive IPF data and TTI-109 progress.

Positives

• Net loss for the fourth quarter of 2025 significantly decreased to $7.3 million from $12.7 million in the comparable period of 2024.
• Full-year 2025 net loss improved to $18.2 million from $29.4 million for the full year 2024.
• Basic and diluted net loss per share improved to $(0.78) in Q4 2025 from $(4.94) in Q4 2024.
• Full-year 2025 basic net loss per share improved to $(2.46) from $(11.42) in 2024.
• Additional analysis from the REVERT IPF Phase 2 trial demonstrated TTI-101 was associated with a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo.
• TTI-101 also showed a 4.5-fold greater decline in IL-6 in the REVERT IPF trial, consistent with preclinical data.
• The healthy volunteer study of the next-generation STAT3 inhibitor, TTI-109, is on track for topline data in the second quarter of 2026.
• Interim results from the REVERT LIVER CANCER trial have already shown clinically meaningful activity of TTI-101 both as monotherapy and in combination with established anti-cancer agents across treatment lines.

Negatives

• Topline data from the Phase 1b/2 REVERT LIVER CANCER trial of TTI-101 in HCC is delayed, now anticipated in the second half of 2026.
• Full-year 2025 general and administrative expenses increased to $8.7 million from $4.5 million in 2024, primarily due to increases in professional fees attributable to the merger with Cara Therapeutics and subsequent public company filings.
• Cash, cash equivalents, and short-term investments slightly decreased to $30.8 million as of December 31, 2025, from $31.6 million as of December 31, 2024.

Risks

• Uncertainties associated with Tvardi's product candidates.
• Risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials.
• Significant net losses incurred since inception.
• Ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance product candidates through clinical development.
• Timing of the availability of data from clinical trials.
• Outcome of preclinical testing and clinical trials of the product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements.
• Plans to research, develop, and commercialize current and future product candidates.
• Clinical utility, potential benefits, and market acceptance of product candidates.
• Requirement for additional capital to continue to advance product candidates, which may not be available on favorable terms or at all.
• Anticipated cash runway.
• Ability to attract, hire, and retain skilled executive officers and employees.
• Ability to protect intellectual property and proprietary technologies.
• Reliance on third parties, contract manufacturers, and contract research organizations.
• Possibility of being adversely affected by other economic, business, or competitive factors.
• Risks associated with changes in applicable laws or regulations.

Future Outlook

Tvardi Therapeutics anticipates topline data from its TTI-109 healthy volunteer study in Q2 2026 and from its TTI-101 REVERT LIVER CANCER Phase 1b/2 trial in H2 2026. The company expects its current cash runway to fund operations into Q4 2026, covering these key clinical readouts.

Management Comments

• "We entered 2026 with line-of-site to two significant clinical milestones: 1) healthy volunteer data from our next-generation STAT3 inhibitor, TTI-109, in the second quarter of this year, and 2) topline data from our ongoing Phase 2 trial of TTI-101 in HCC, which we anticipate in the second half."
• "Further analysis of data from our Phase 2 IPF trial of TTI-101 that we announced in October revealed compelling trends. These data give us optimism for TTI-109, which has been developed to enhance TTI-101s ability to target STAT3 as a more efficient delivery vehicle with the potential to improve tolerability."
• "Interim results from this study [REVERT LIVER CANCER] have already shown clinically meaningful activity of TTI-101 both as monotherapy and in combination with established anti-cancer agents across treatment lines, and we believe the broader dataset will better position us to define the optimal development path and regulatory strategy for this important program."
• "I believe we are well positioned to continue to advance these promising molecules, potentially offering new hope to patients requiring new, more effective treatment options while creating enduring value for our company."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry places high value on clinical trial progress and data readouts, especially for novel mechanisms like STAT3 inhibition. Delays, even for strategic reasons, can impact investor sentiment, while positive interim data and pipeline advancement, such as with TTI-109, are crucial for long-term valuation in a competitive oncology and inflammatory disease landscape.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for increased volatility due to delayed clinical data, but also positive financial trends and pipeline progress.
• Patients: Continued hope for new treatment options for inflammatory and proliferative diseases, particularly HCC and IPF, with ongoing clinical development.
• Employees: Continued focus on advancing promising molecules, suggesting stability in R&D efforts.
• Creditors/Suppliers: Financial improvements and a cash runway into Q4 2026 suggest continued operational viability.

Next Steps

• Preliminary topline data from a healthy volunteer study of TTI-109 anticipated in Q2 2026.
• Preliminary topline data from the REVERT LIVER CANCER Phase 1b/2 clinical trial of TTI-101 anticipated in H2 2026.
• Further data maturation, longitudinal and translational assessments, characterization of durability, and dose optimization for the REVERT LIVER CANCER trial.
• Addition of up to 15 participants in the monotherapy arm of the REVERT LIVER CANCER trial to explore once-a-day dosing.
• Define the optimal development path and regulatory strategy for the TTI-101 HCC program.

Key Dates

Recommendation

The filing presents a mixed bag for investors. While Tvardi Therapeutics demonstrated significant improvements in financial performance with reduced net losses and improved EPS, the delay in topline data for the critical TTI-101 HCC trial introduces a notable element of uncertainty and could temper immediate investor enthusiasm. This delay, though explained as strategic for data maturation, pushes back a key catalyst. However, the positive additional analysis from the TTI-101 IPF trial and the on-track progress for the next-generation TTI-109 provide some offsetting positives. Given these conflicting signals, a 'hold' recommendation is appropriate, allowing investors to await the upcoming clinical readouts in Q2 and H2 2026 before making further investment decisions.

Keywords

Tvardi Therapeutics, TVRD, STAT3 inhibitor, TTI-101, TTI-109, Hepatocellular Carcinoma, HCC, Idiopathic Pulmonary Fibrosis, IPF, biopharmaceutical, clinical trial, financial results, drug development, oncology, fibrosis